As skeletal muscle atrophy in CKD can result from several interrelated mechanisms leading to an imbalance between protein synthesis and degradation4,23, we further investigated whether the beneficial effects of FGF19 could implicate pathways such as the ubiquitin–proteasome or myostatin. The gene discussed is MSTN; the disease is chronic kidney disease.